Clinical trials · Alabama
Atherosclerotic Cardiovascular Disease clinical trials in Alabama
We’re tracking 8 recruiting atherosclerotic cardiovascular disease studies with a site in Alabama — including Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Alabama
- NCT07037433RecruitingPhase 3
Heart protection study for people with heart disease and overweight
This study tests a new weekly injection (maridebart cafraglutide) to see if it helps lower the risk of heart problems in people with heart disease and overweight. It is for adults who have had a heart attack, stroke, or artery blockages and also have a BMI of 27 or higher.
Daphne, AlabamaAges 45–99 - NCT06930885RecruitingPhase 3
Polypill and colchicine for heart and artery risk
This trial tests a combination pill (polypill) and a medicine called colchicine to see if they can lower the risk of future heart attacks, strokes, or other artery problems. It is for people who already have a history of heart or blood vessel disease.
Maceió, AlabamaAges 45 years+ - NCT06813911RecruitingPhase 3
Testing pelacarsen for high Lp(a) in heart disease patients
This trial tests a new medicine called pelacarsen for people with very high Lp(a) (a type of cholesterol) and existing heart or blood vessel disease. It aims to see if adding pelacarsen to your current cholesterol treatment can lower your Lp(a) levels further.
Birmingham, AlabamaAges 18–80 - NCT06875973RecruitingPhase 3
Pelacarsen long-term extension study
This trial is for people who have already finished taking pelacarsen in a previous study. It offers continued access to the drug and checks long-term safety.
Birmingham, AlabamaAges 18–100 - NCT06962488Recruiting
Personalized blood pressure care using genetic risk
This study uses your genetic information (a polygenic risk score) to guide personalized blood pressure management. It aims to help people with high blood pressure and overall poor heart health improve their levels through tailored advice.
Birmingham, AlabamaAges 18–55 - NCT07136012RecruitingPhase 3
Olpasiran trial to lower Lp(a) and prevent first heart attack or stroke
This trial tests if olpasiran can lower a type of cholesterol called Lp(a) to help prevent a first major heart attack, stroke, or other heart problems. It is for people at higher risk due to risk factors or early signs of artery disease, but who have not yet had a heart attack or stroke.
Alexander City, AlabamaAges 50–105 - NCT07000357RecruitingPhase 3
Study of AZD0780 to reduce heart attack and stroke risk
This trial tests a new medication, AZD0780, to see if it helps prevent major cardiovascular events like heart attacks or strokes in people who already have heart or blood vessel disease, or are at high risk for a first event. It might be a good fit if your cholesterol isn't well-controlled despite current treatments.
Foley, AlabamaAges 18 years+ - NCT05390892RecruitingPhase 4
Preventing kidney and heart damage in type 2 diabetes
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Huntsville, AlabamaAges 40–80
Where these studies are running in Alabama
Institutions with a site for the recruiting atherosclerotic cardiovascular disease studies listed above.
- Alliance For Multispecialty Research - Daphne · 2 studies
- Eastern Shore Research Institute, LLC · 2 studies
- Heart Center Research LLC · 2 studies
- Parkway Medical Center · 2 studies
- University of Alabama at Birmingham · 2 studies
- Advanced Cardiovascular, LLC
- CB Flock Research Corporation
- Centro de Pesquisas Clínicas Dr. Marco Mota
What taking part in a atherosclerotic cardiovascular disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Atherosclerotic Cardiovascular Disease trials in other states
Common questions
- Are there atherosclerotic cardiovascular disease clinical trials in Alabama?
- Yes. We're currently tracking 8 recruiting atherosclerotic cardiovascular disease studies with a site in Alabama, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a atherosclerotic cardiovascular disease study in Alabama?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Alabama to take part?
- Not necessarily. These studies have a site in Alabama, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a atherosclerotic cardiovascular disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New atherosclerotic cardiovascular disease studies open in Alabama regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.